Asset profile
REGEND001
Cell therapy
Evidence outlook · lead readout
NCT05638776 · Chronic Obstructive Pulmonary Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05638776: The trial randomly assigned 58 participants to REGEND001 or placebo and blinded participants, but the primary outcome was change in DLCO, a physiological surrogate rather than a direct clinical outcome. Because the registry does not report whether this primary comparison was successful, the evidence is currently limited to the trial design.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.